Spots Global Cancer Trial Database for selinexor
Every month we try and update this database with for selinexor cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Single Patient Use of Selinexor and Dexamethasone for a Patient With Multiple Myeloma | NCT03850704 | Multiple Myelom... | Selinexor | 18 Years - | Masonic Cancer Center, University of Minnesota | |
| Selinexor and Chemotherapy in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia | NCT02299518 | Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Recurrent Adult... Secondary Acute... | mitoxantrone hy... etoposide cytarabine selinexor laboratory biom... pharmacological... | 18 Years - | Ohio State University Comprehensive Cancer Center | |
| Selinexor Combined With R-GemOx as Second-line Treatment in Patients With Diffuse Large B-cell Lymphoma | NCT05786989 | Diffuse Large B... | selinexor | 18 Years - 75 Years | Chongqing University Cancer Hospital | |
| Gemcitabine, Nab-paclitaxel and KPT-330 in Advanced Pancreatic Cancer | NCT02178436 | Acinar Cell Ade... Duct Cell Adeno... Stage IV Pancre... | gemcitabine hyd... Selinexor Pharmacological... Laboratory Biom... Nab paclitaxel | 19 Years - | Barbara Ann Karmanos Cancer Institute | |
| Selinexor With Fludarabine and Cytarabine for Treatment of Refractory or Relapsed Leukemia or Myelodysplastic Syndrome | NCT02212561 | Acute Myeloid L... Acute Lymphobla... Myelodysplastic... Mixed Phenotype... | Selinexor Fludarabine Cytarabine methotrexate/hy... | - 24 Years | St. Jude Children's Research Hospital | |
| Study of Selinexor and Venetoclax in Combination With Chemotherapy in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia | NCT04898894 | Acute Leukemia ... Acute Myeloid L... Refractory Acut... Refractory Acut... | Venetoclax Selinexor Cytarabine Fludarabine Filgrastim Methotrexate methotrexate/hy... | 2 Years - 30 Years | St. Jude Children's Research Hospital | |
| Selinexor Plus Gemcitabine in Selected Advanced Soft-tissue Sarcoma and Osteosarcoma | NCT04595994 | Sarcoma,Soft Ti... | Selinexor | 18 Years - 80 Years | Grupo Espanol de Investigacion en Sarcomas | |
| A Study of Selinexor in Combination With Azacitidine and Venetoclax (SAV Regimen) in Treatment Naïve Participants With Acute Myeloid Leukemia | NCT05736965 | AML, Adult | Selinexor Azacitidine Venetoclax | 18 Years - | Shanghai Tong Ren Hospital | |
| Testing the Addition of an Anti-cancer Drug, Selinexor, to the Usual Chemotherapy Treatment (Temozolomide) for Brain Tumors That Have Returned After Previous Treatment | NCT05432804 | MGMT-Methylated... Recurrent Gliob... Recurrent MGMT-... | Biospecimen Col... Magnetic Resona... Selinexor Temozolomide | 18 Years - | National Cancer Institute (NCI) | |
| Phase 1/2 Trial of Selinexor (KPT-330) With Docetaxel for Non-small Cell Lung Cancer (NSCLC) | NCT03095612 | Non-small Cell ... | Selinexor Docetaxel | 18 Years - | University of Texas Southwestern Medical Center | |
| Safety and Efficacy of Selinexor in Combination With Pembrolizumab in Recurrent Advanced Melanoma | NCT04768881 | Locally Advance... | Selinexor Pembrolizumab | 18 Years - | Karyopharm Therapeutics Inc | |
| Safety Study of KPT-330 (Selinexor) in Patients With Advanced or Metastatic Solid Tumor Cancer | NCT01607905 | Solid Tumor | Selinexor Acetaminophen | 18 Years - | Karyopharm Therapeutics Inc | |
| A Study of Selinexor in Combination With Standard of Care Therapy for Newly Diagnosed or Recurrent Glioblastoma | NCT04421378 | Glioblastoma Mu... | Selinexor Temozolomide (T... Lomustine (CCNU... Standard Fracti... Bevacizumab TTField Carmustine | 18 Years - | Karyopharm Therapeutics Inc | |
| A Study of Selinexor (Seli) + Low-dose Dexamethasone (LDD) in Penta-refractory Multiple Myeloma (MM), Seli and Bortezomib + LDD in Triple-class Refractory MM, and Seli and Pomalidomide + LDD in Relapsed Refractory MM | NCT04414475 | Multiple Myelom... | Selinexor Dexamethasone Bortezomib Pomalidomide | 18 Years - | Karyopharm Therapeutics Inc | |
| SHIP (Selinexor in Hormone Insensitive Prostate Cancer) | NCT02146833 | Prostate Cancer | Selinexor | 18 Years - | Karyopharm Therapeutics Inc | |
| Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies | NCT02419495 | Advanced Malign... Clinical Stage ... Clinical Stage ... Fallopian Tube ... Metastatic Lung... Metastatic Mali... Metastatic Mela... Metastatic Rena... Ovarian Carcino... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Primary Periton... Stage III Lung ... Stage III Renal... Stage IIIA Lung... Stage IIIB Lung... Stage IIIC Lung... Stage IV Lung C... Stage IV Renal ... Stage IVA Lung ... Stage IVB Lung ... Triple-Negative... Unresectable Lu... Unresectable Me... Unresectable Re... | Capecitabine Carboplatin Cyclophosphamid... Doxorubicin Eribulin Fluorouracil Ipilimumab Irinotecan Hydr... Leucovorin Calc... Nivolumab Olaparib Oxaliplatin Paclitaxel Pembrolizumab Pemetrexed Selinexor Topotecan | 18 Years - | M.D. Anderson Cancer Center | |
| A Study of Selinexor (Seli) + Low-dose Dexamethasone (LDD) in Penta-refractory Multiple Myeloma (MM), Seli and Bortezomib + LDD in Triple-class Refractory MM, and Seli and Pomalidomide + LDD in Relapsed Refractory MM | NCT04414475 | Multiple Myelom... | Selinexor Dexamethasone Bortezomib Pomalidomide | 18 Years - | Karyopharm Therapeutics Inc | |
| A Study of Selinexor (Seli) + Low-dose Dexamethasone (LDD) in Penta-refractory Multiple Myeloma (MM), Seli and Bortezomib + LDD in Triple-class Refractory MM, and Seli and Pomalidomide + LDD in Relapsed Refractory MM | NCT04414475 | Multiple Myelom... | Selinexor Dexamethasone Bortezomib Pomalidomide | 18 Years - | Karyopharm Therapeutics Inc | |
| Selinexor, Cyclophosphamide and Prednisone in Myeloma | NCT06212596 | Relapsed or Ref... | Selinexor Cyclophosphamid... Prednisone | 18 Years - | University of Leeds | |
| Selinexor in Treating Patients With Relapsed Small Cell Lung Cancer | NCT02351505 | Recurrent Small... | Selinexor Laboratory Biom... Pharmacological... | 18 Years - | Ohio State University Comprehensive Cancer Center | |
| A Study of Selinexor in People With Wilms Tumors and Other Solid Tumors | NCT05985161 | Wilms Tumor Rhabdoid Tumor Malignant Perip... MPNST Nephroblastoma XPO1 Gene Mutat... Solid Tumor | Selinexor | 12 Months - | Memorial Sloan Kettering Cancer Center | |
| A Study of Selinexor, in Combination With Carfilzomib, Daratumumab or Pomalidomide in Patients With Multiple Myeloma | NCT04661137 | Multiple Myelom... | Selinexor 60 MG Selinexor 80 MG Selinexor 100 M... Carfilzomib Pomalidomide Daratumumab Dexamethasone | 18 Years - | Hackensack Meridian Health | |
| Selinexor (KPT-330) Plus FLAG-Ida for the Treatment of Relapsing/Refractory AML | NCT03661515 | Acute Myeloid L... | Selinexor fludarabine idarubicin cytarabine G-CSF | 18 Years - 65 Years | PETHEMA Foundation | |
| Selinexor Treatment for Multiple Myeloma Patients Who Are Refractory to Lenalidomide-containing Therapy. | NCT04519476 | Refractory Mult... | Selinexor Lenalidomide Methylprednisol... | 18 Years - | Oncotherapeutics | |
| Selinexor for the Treatment of Intermediate and High-Risk Smoldering Multiple Myeloma | NCT05597345 | Smoldering Mult... | Selinexor | 18 Years - | University of Rochester | |
| Selinexor, Pomalidomide, and Dexamethasone With or Without Carfilzomib for the Treatment of Patients With Relapsed Refractory Multiple Myeloma, The SCOPE Trial | NCT04764942 | Recurrent Multi... Refractory Mult... | Carfilzomib Dexamethasone Pomalidomide Quality-of-Life... Questionnaire A... Selinexor X-Ray Imaging Computed Tomogr... Positron Emissi... Bone Marrow Bio... Bone Marrow Asp... Biospecimen Col... | 18 Years - | Mayo Clinic | |
| Testing Atezolizumab With or Without Selinexor in Patients >= 18 Years Old With Alveolar Soft Part Sarcoma, the Axiom Study | NCT05333458 | Advanced Alveol... Advanced Soft T... Metastatic Alve... Unresectable Al... | Atezolizumab Biopsy Biospecimen Col... Computed Tomogr... Magnetic Resona... Selinexor | 18 Years - | National Cancer Institute (NCI) | |
| Selinexor in Treating Younger Patients With Recurrent or Refractory Solid Tumors or High-Grade Gliomas | NCT02323880 | Malignant Gliom... Recurrent Brain... Recurrent Child... Recurrent Child... Recurrent Lymph... Recurrent Malig... Refractory Lymp... Refractory Mali... Refractory Prim... WHO Grade 3 Gli... | Pharmacological... Selinexor | 12 Months - 21 Years | Children's Oncology Group | |
| Selinexor in Treating Patients With Intermediate- and High-Risk Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome After Transplant | NCT02485535 | Acute Myeloid L... de Novo Myelody... Myelodysplastic... Secondary Acute... Secondary Myelo... | Laboratory Biom... Selinexor | - | University of Chicago | |
| Maintenance With Selinexor/Placebo After Combination Chemotherapy in Participants With Endometrial Cancer [SIENDO] | NCT03555422 | Endometrial Can... | Selinexor Matching placeb... | 18 Years - | Karyopharm Therapeutics Inc | |
| A Study of Selinexor in People With Wilms Tumors and Other Solid Tumors | NCT05985161 | Wilms Tumor Rhabdoid Tumor Malignant Perip... MPNST Nephroblastoma XPO1 Gene Mutat... Solid Tumor | Selinexor | 12 Months - | Memorial Sloan Kettering Cancer Center | |
| Maintenance With Selinexor/Placebo After Combination Chemotherapy in Participants With Endometrial Cancer [SIENDO] | NCT03555422 | Endometrial Can... | Selinexor Matching placeb... | 18 Years - | Karyopharm Therapeutics Inc | |
| Low-Dose Selinexor and Choline Salicylate for Non-Hodgkin or Hodgkin Lymphoma, Histiocytic/Dendritic Cell Neoplasm, or Relapsed or Refractory Multiple Myeloma | NCT04640779 | Recurrent Histi... Recurrent Hodgk... Recurrent Non-H... Recurrent Plasm... Refractory Hist... Refractory Hodg... Refractory Non-... Refractory Plas... | Choline Salicyl... Selinexor | 18 Years - | Mayo Clinic | |
| Selinexor and Pembrolizumab for the Treatment of Cisplatin-Ineligible or Cisplatin-Refractory Locally Advanced or Metastatic Urothelial Carcinoma | NCT04856189 | Advanced Urothe... Locally Advance... Metastatic Urot... Refractory Urot... | Pembrolizumab Selinexor | 18 Years - | University of California, Davis | |
| Phase 1 Trial To Evaluate mFOLFOX6 With Selinexor In Patients With Metastatic Colorectal Cancer | NCT02384850 | Colorectal Neop... | Selinexor Oxaliplatin 5-FU Folinic Acid | 18 Years - | GSO Global Clinical Research BV | |
| A Study of Different Dosing Schedules of Selinexor in Sarcoma Patients | NCT04811196 | Soft Tissue Sar... Malignant Perip... Leiomyosarcoma Endometrial Str... | Selinexor | 18 Years - | University Health Network, Toronto | |
| Phase 1 Trial To Evaluate mFOLFOX6 With Selinexor In Patients With Metastatic Colorectal Cancer | NCT02384850 | Colorectal Neop... | Selinexor Oxaliplatin 5-FU Folinic Acid | 18 Years - | GSO Global Clinical Research BV | |
| Selinexor (Nexpovio®) (SVd) in Patients With Relapsed or Refractory Multiple Myeloma - SEATTLE- | NCT05954780 | Multiple Myelom... | Selinexor | 18 Years - | iOMEDICO AG | |
| Selinexor in Combination With Ixazomib for the Treatment of Advanced Sarcoma | NCT03880123 | Liposarcoma Malignant Perip... Alveolar Soft P... Ewing Sarcoma Sarcoma | Selinexor Ixazomib | 14 Years - | Columbia University | |
| Selinexor (KPT-330) in Combination With Temozolomide and Radiation Therapy in Patients With Newly Diagnosed Glioblastoma | NCT04216329 | Gliosarcoma Newly Diagnosed Glioblastoma | Selinexor Temozolomide Generic Radiati... | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Selinexor With Combination With Induction/Consolidation Therapy in Acute Myeloid Leukemia Patients | NCT02835222 | Untreated Adult... | Cytarabine Daunorubicin Hy... Selinexor | 18 Years - | Wake Forest University Health Sciences | |
| Selinexor (KPT-330) in Combination With Temozolomide and Radiation Therapy in Patients With Newly Diagnosed Glioblastoma | NCT04216329 | Gliosarcoma Newly Diagnosed Glioblastoma | Selinexor Temozolomide Generic Radiati... | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| A Study of Different Dosing Schedules of Selinexor in Sarcoma Patients | NCT04811196 | Soft Tissue Sar... Malignant Perip... Leiomyosarcoma Endometrial Str... | Selinexor | 18 Years - | University Health Network, Toronto | |
| A Phase Ib Study of Oral Selinexor in Adult Patients With Relapsed/Refractory B-cell Lymphoma Receiving R-DHAOx or R-GDP | NCT02741388 | B-cell Lymphoma | selinexor Rituximab Dexamethasone Oxaliplatin Cisplatin Cytarabine Gemcitabine | 18 Years - 70 Years | The Lymphoma Academic Research Organisation | |
| Selinexor With Combination With Induction/Consolidation Therapy in Acute Myeloid Leukemia Patients | NCT02835222 | Untreated Adult... | Cytarabine Daunorubicin Hy... Selinexor | 18 Years - | Wake Forest University Health Sciences | |
| Selinexor in Combination With Ixazomib for the Treatment of Advanced Sarcoma | NCT03880123 | Liposarcoma Malignant Perip... Alveolar Soft P... Ewing Sarcoma Sarcoma | Selinexor Ixazomib | 14 Years - | Columbia University | |
| A Study of Selinexor in Combination With Daunorubicin and Cytarabine for Untreated AML | NCT02403310 | Leukemia Acute Myeloid L... AML | Selinexor Daunorubicin Cytarabine | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Selinexor in Treating Patients With Abiraterone Acetate and/or Enzalutamide Refractory Metastatic Castration-Resistant Prostate Cancer | NCT02215161 | Castration Leve... Hormone-Resista... Metastatic Pros... Prostate Carcin... PSA Progression Stage IV Prosta... | Selinexor | 18 Years - | University of California, San Francisco | |
| Testing the Addition of an Anti-cancer Drug, Selinexor, to the Usual Chemotherapy Treatment (Temozolomide) for Brain Tumors That Have Returned After Previous Treatment | NCT05432804 | MGMT-Methylated... Recurrent Gliob... Recurrent MGMT-... | Biospecimen Col... Magnetic Resona... Selinexor Temozolomide | 18 Years - | National Cancer Institute (NCI) | |
| Study Assessing Activity of Intravenous (IV) ABBV-383 Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma | NCT06158841 | Multiple Myelom... | ABBV-383 Carfilzomib Pomalidomide Elotuzumab Selinexor Bortezomib Dexamethasone | 18 Years - | AbbVie | |
| Selinexor, Daratumumab, Carfilzomib and Dexamethasone for the Treatment of High-Risk, Recurrent or Refractory Multiple Myeloma | NCT04756401 | Recurrent Plasm... Refractory Plas... | Carfilzomib Daratumumab Dexamethasone Quality-of-Life... Selinexor | 18 Years - | Academic and Community Cancer Research United | |
| Selinexor Plus High-Dose Melphalan (HDM) Before Autologous Hematopoietic Cell Transplantation for Multiple Myeloma | NCT02780609 | Multiple Myelom... | Selinexor Melphalan Dexamethasone Autologous Hema... Fosaprepitant | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| SVRd for the Treatment of Newly Diagnosed Multiple Myeloma Patients Presenting With Extramedullary Disease | NCT05900882 | Multiple Myelom... | Selinexor Bortezomib Lenalidomide Dexamethasone | 18 Years - 75 Years | The First Affiliated Hospital with Nanjing Medical University | |
| Selinexor Combination Ph 1 Study | NCT05177276 | Solid Tumor Mal... | Selinexor Irinotecan | 18 Years - | Hackensack Meridian Health | |
| Selinexor Combined With Standard Chemoradiation as Neoadjuvant Treatment in Locally Advanced Rectal Cancer | NCT02137356 | Rectal Neoplasm... | standard dose p... standard dose c... dose-escalated ... | 18 Years - | Sheba Medical Center | |
| Selinexor, Carfilzomib, and Dexamethasone Versus Placebo, Carfilzomib, and Dexamethasone in Multiple Myeloma | NCT02628704 | Multiple Myelom... | Selinexor Placebo (for se... carfilzomib Dexamethasone | 18 Years - | Karyopharm Therapeutics Inc | |
| Study of CLAG + Selinexor in Relapsed or Refractory Acute Myeloid Leukemia | NCT02416908 | Acute Myeloid L... | Selinexor Cladribine G-CSF Cytarabine Bone marrow bio... | 18 Years - 70 Years | Washington University School of Medicine | |
| Testing the Addition of an Anti-cancer Drug, Selinexor, to the Usual Chemotherapy Treatment (Temozolomide) for Brain Tumors That Have Returned After Previous Treatment | NCT05432804 | MGMT-Methylated... Recurrent Gliob... Recurrent MGMT-... | Biospecimen Col... Magnetic Resona... Selinexor Temozolomide | 18 Years - | National Cancer Institute (NCI) | |
| Treatment of Selinexor in Combination With Clarithromycin, Pomalidomide and Dexamethasone for Relapsed Refractory Multiple Myeloma Patients | NCT04843579 | Myeloma Multipl... Myeloma Refractory Mult... | Selinexor Clarithromycin Pomalidomide Dexamethasone | 18 Years - 74 Years | Weill Medical College of Cornell University | |
| Safety Study of the Selective Inhibitor of Nuclear Export (SINE) KPT-330 in Patients With Advanced Hematological Cancer | NCT01607892 | Hematological M... | KPT-330 | 18 Years - | Karyopharm Therapeutics Inc | |
| SELIBORDARA: Selinexor, Bortezomib and Daratumumab in Multiple Myeloma | NCT03589222 | Refractory Mult... | Selinexor Daratumumab Bortezomib Dexamethasone | 18 Years - | PETHEMA Foundation | |
| Maintenance With Selinexor/Placebo After Combination Chemotherapy in Participants With Endometrial Cancer [SIENDO] | NCT03555422 | Endometrial Can... | Selinexor Matching placeb... | 18 Years - | Karyopharm Therapeutics Inc | |
| Study of Selinexor in Combination With Backbone Treatments or Novel Therapies In Participants With Relapsed or Refractory (RR) Diffuse Large B-Cell Lymphoma (DLBCL) | NCT04607772 | Relapsed or Ref... | Selinexor Rituximab Bendamustine Polatuzumab Ved... Ibrutinib Lenalidomide Tafasitamab Venetoclax Gemcitabine Oxaliplatin | 18 Years - | Karyopharm Therapeutics Inc | |
| Selinexor, Pomalidomide, and Dexamethasone With or Without Carfilzomib for the Treatment of Patients With Relapsed Refractory Multiple Myeloma, The SCOPE Trial | NCT04764942 | Recurrent Multi... Refractory Mult... | Carfilzomib Dexamethasone Pomalidomide Quality-of-Life... Questionnaire A... Selinexor X-Ray Imaging Computed Tomogr... Positron Emissi... Bone Marrow Bio... Bone Marrow Asp... Biospecimen Col... | 18 Years - | Mayo Clinic | |
| Selinexor in Patients With Advanced Thymoma and Thymic Carcinoma | NCT03466827 | Thymoma Advanced Thymic... | Selinexor | 18 Years - | Rigshospitalet, Denmark | |
| Selinexor Combined With R-GemOx as Second-line Treatment in Patients With Diffuse Large B-cell Lymphoma | NCT05786989 | Diffuse Large B... | selinexor | 18 Years - 75 Years | Chongqing University Cancer Hospital | |
| Selinexor and Pembrolizumab for the Treatment of Cisplatin-Ineligible or Cisplatin-Refractory Locally Advanced or Metastatic Urothelial Carcinoma | NCT04856189 | Advanced Urothe... Locally Advance... Metastatic Urot... Refractory Urot... | Pembrolizumab Selinexor | 18 Years - | University of California, Davis | |
| NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS) | NCT06239272 | Non-rhabdomyosa... Adipocytic Neop... Liposarcoma | Surgical resect... Proton beam rad... Pazopanib Ifosfamide Doxorubicin Selinexor | - 30 Years | St. Jude Children's Research Hospital | |
| Selinexor in Patients With Advanced Thymic Epithelial Tumor Progressing After Primary Chemotherapy | NCT03193437 | Thymoma Advanced Thymic... | Open Label Seli... | 18 Years - | Georgetown University | |
| Efficacy & Safety Study of KPT-330 in Erythropoietin-Refractory Lower-Risk Myelodysplastic Syndrome Patients | NCT02431351 | Myelodysplastic... | Selinexor | 18 Years - | Karyopharm Therapeutics Inc | |
| Selinexor in Combination With Fludarabine and Cytarabine in Patients With Refractory or Relapsed Acute Myeloid Leukemia | NCT03071276 | Acute Myeloid L... | Selinexor Fludarabine Cytarabine methotrexate/hy... | - 24 Years | St. Jude Children's Research Hospital | |
| Novel Combination Therapy in the Treatment of Relapsed and Refractory Aggressive B-Cell Lymphoma | NCT02436707 | Lymphoma | Ibrutinib Rituximab Gemcitabine Dexamethasone Cisplatin Mesna Cyclophosphamid... Etoposide G-CSF Selinexor | 16 Years - 65 Years | Canadian Cancer Trials Group | |
| Safety Study of the Selective Inhibitor of Nuclear Export (SINE) KPT-330 in Patients With Advanced Hematological Cancer | NCT01607892 | Hematological M... | KPT-330 | 18 Years - | Karyopharm Therapeutics Inc | |
| Phase I Trial of Selinexor (KPT-330) and Ifosfamide, Carboplatin, Etoposide (ICE) in Peripheral T-cell Lymphoma | NCT03212937 | Peripheral T-ce... | Selinexor ICE Chemotherap... | 18 Years - 90 Years | National Cancer Centre, Singapore | |
| Bortezomib, Selinexor, and Dexamethasone in Patients With Multiple Myeloma | NCT03110562 | Multiple Myelom... | Selinexor Bortezomib Dexamethasone | 18 Years - | Karyopharm Therapeutics Inc | |
| Comparing the Combination of Selinexor-Daratumumab-Velcade-Dexamethasone (Dara-SVD) With the Usual Treatment (Dara-RVD) for High-Risk Newly Diagnosed Multiple Myeloma | NCT06169215 | Multiple Myelom... | Biospecimen Col... Bone Marrow Bio... Bortezomib Computed Tomogr... Daratumumab Daratumumab and... Dexamethasone Lenalidomide Magnetic Resona... Positron Emissi... Selinexor | - | National Cancer Institute (NCI) | |
| A Trial of Selinexor, Ruxolitinib and Methylprednisolone | NCT06225310 | Multiple Myelom... Multiple Myelom... | Selinexor Ruxolitinib Methylprednisol... | - | Oncotherapeutics | |
| Selinexor, Carfilzomib, and Dexamethasone Versus Placebo, Carfilzomib, and Dexamethasone in Multiple Myeloma | NCT02628704 | Multiple Myelom... | Selinexor Placebo (for se... carfilzomib Dexamethasone | 18 Years - | Karyopharm Therapeutics Inc | |
| Selinexor, Cyclophosphamide and Prednisone in Myeloma | NCT06212596 | Relapsed or Ref... | Selinexor Cyclophosphamid... Prednisone | 18 Years - | University of Leeds | |
| Selinexor Treatment of Refractory Myeloma | NCT02336815 | Multiple Myelom... | Selinexor Dexamethasone | 18 Years - | Karyopharm Therapeutics Inc |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
